Cost-effectiveness of pharmacist care for managing patients at high risk for cardiovascular disease in Canada

被引：0
|
作者：
Al Hamarneh, Y. N. [1 ]
Johnston, K. [2 ]
Marra, C. [3 ]
Tsuyuki, R. [1 ]
机构：
[1] Univ Alberta, Edmonton, AB, Canada
[2] Broadst HEOR, Vancouver, BC, Canada
[3] Univ Otago, Dunedin, New Zealand
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2019年 / 41卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PEC002
引用
收藏
页码：297 / 298
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF A POLYPILL FOR PATIENTS WITH OR AT HIGH RISK OF CARDIOVASCULAR DISEASE IN AN NHS SETTING
    Crossan, C. J.
    Dehbi, H.
    Thom, S.
    Poulter, N.
    Lord, J.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A620 - A620
  • [2] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [3] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
  • [4] Pharmacist prescribing and care improves cardiovascular risk, but is it cost-effective? A cost-effectiveness analysis of the RxEACH study
    Al Hamarneh, Yazid N.
    Johnston, Karissa
    Marra, Carlo A.
    Tsuyuki, Ross T.
    [J]. CANADIAN PHARMACISTS JOURNAL, 2019, 152 (04) : 257 - 266
  • [5] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Gregoire, Jean
    Champsi, Salimah
    Jobin, Manon
    Martinez, Laura
    Urbich, Michael
    Rogoza, Raina M.
    [J]. ADVANCES IN THERAPY, 2022, 39 (07) : 3262 - 3279
  • [6] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Jean Grégoire
    Salimah Champsi
    Manon Jobin
    Laura Martinez
    Michael Urbich
    Raina M. Rogoza
    [J]. Advances in Therapy, 2022, 39 : 3262 - 3279
  • [7] Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
    Lindgren, P.
    Hagstrom, E.
    Van Hout, B.
    Villa, G.
    Urbich, M.
    Sandelin, R.
    Svensson, M. Eriksson
    Fonarow, G. C.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 681 - 681
  • [8] Cost-Effectiveness of Pharmacist Prescribing for Managing Hypertension in the United States
    Dixon, Dave L.
    Johnston, Karissa
    Patterson, Julie
    Marra, Carlo A.
    Tsuyuki, Ross T.
    [J]. JAMA NETWORK OPEN, 2023, 6 (11) : E2341408
  • [9] Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    van Hout, Ben
    Villa, Guillermo
    Arellano, Jorge
    Lindgren, Peter
    [J]. JAMA CARDIOLOGY, 2019, 4 (07) : 691 - 695
  • [10] Cost-effectiveness of ramipril in preventing cardiovascular events in high-risk patients
    Ganguly, R
    Parasuraman, TV
    [J]. VALUE IN HEALTH, 2003, 6 (03) : 321 - 322
12345